Drug intelligence / Profile preview

hydrochlorothiazide + metoprolol

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

Hydrochlorothiazide + metoprolol is an oral fixed-dose combination antihypertensive product composed of two **small-molecule** agents: metoprolol, a selective beta-1 adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic. It is used to treat **hypertension** and is generally intended for patients whose blood pressure has already been titrated on the individual components rather than for initial therapy. The combination lowers blood pressure through complementary mechanisms: metoprolol reduces heart rate, myocardial contractility, and renin release via beta-1 blockade, while hydrochlorothiazide promotes renal sodium and water excretion by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule. Marketed versions have included **Lopressor HCT** and **Dutoprol**, reflecting different metoprolol salt and release-formulation presentations.

Brand names
Lopressor HCTDutoprol
Other names
metoprolol tartrate + hydrochlorothiazidemetoprolol succinate + hydrochlorothiazidemetoprolol tartrate and hydrochlorothiazidemetoprolol succinate and hydrochlorothiazide
02

Targets

SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)ADRB1 (β1)

Beyond the preview

Go deeper on hydrochlorothiazide + metoprolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydrochlorothiazide + metoprolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call